Objective Criteria ID Those With No Chance of Survival in OHCA

Share this content:
Objective Criteria ID Those With No Chance of Survival in OHCA
Objective Criteria ID Those With No Chance of Survival in OHCA

TUESDAY, Sept. 13, 2016 (HealthDay News) -- For patients with out-of-hospital cardiac arrest (OHCA), objective criteria enable early identification of those with no chance of survival, according to research published online Sept. 13 in the Annals of Internal Medicine.

Patricia Jabre, M.D., Ph.D., from the Paris Cardiovascular Research Center, and colleagues examined objective criteria for identifying patients with OHCA with no chance of survival during the first minutes of cardiopulmonary resuscitation. Retrospective data from two registries and one trial were reviewed for 1,771 patients from the Paris Sudden Death Expertise Center (SDEC) prospective cohort and for 5,192 patients from validation cohorts. The authors evaluated thee objective criteria: OHCA not witnessed by emergency medical services personnel, nonshockable initial cardiac rhythm, and no return of spontaneous circulation before receipt of a third dose of epinephrine.

The researchers found that the survival rate among 772 patients with OHCA who met the objective criteria was 0 percent in the Paris SDEC one-year cohort (specificity, 100 percent; positive predictive value, 100 percent). In the validation cohorts these results were verified. Twelve percent of patients from the Paris SDEC one-year cohort may have been eligible for organ donation.

"The three objective criteria enable the early identification of patients with OHCA with essentially no chance of survival and may help in decision making about the organ donation process," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days

AAN: New Drug May Help Infants With Spinal Muscular Atrophy

AAN: New Drug May Help Infants With Spinal ...

RG7916 increases survival motor neuron protein level, with 6.5-fold increase noted with highest dose

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small overall effect size for frequent and heavy cannabis use among adolescents, young adults

is free, fast, and customized just for you!

Already a member?

Sign In Now »